Trial Profile
Bone scan index as a response biomarker for enzalutamide in patients with metastatic castration-resistant prostate cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Aug 2015
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- 25 Aug 2015 New trial record